Cytomegalovirus (CMV) | Niche & Rare Disease Landscape & Forecast | US/EU5 | 2016
The CMV market targets patients with immunodeficiencies, particularly patients receiving solid organ or hematopoietic stem cell transplants. Current therapies have strong antiviral activity but notable side effects, in particular myelotoxicity. These safety issues and a lack of alternative therapies contribute to the substantial unmet need for additional therapeutic options. Several companies are developing novel antivirals, adoptive cell therapies, and therapeutic and prophylactic vaccines to address various aspects of CMV. The anticipated launch of these agents is expected to transform the CMV space and give patients with high unmet need much-needed treatment options.
Related Market Assessment Reports
Report
Eosinophilic Esophagitis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Eosinophilic Esophagitis (US)
Eosinophilic esophagitis (EoE) is a chronic allergic inflammatory condition of the esophagus, marked by an accumulation of eosinophils. This can lead to difficulty swallowing and potentially…
Report
Metabolic Dysfunction-Associated Steatohepatitis – Unmet Need – Unmet Need – Metabolic Dysfunction-Associated Steatohepatitis (US/EU)
Metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH), has the potential to be a large and lucrative therapy market owing to the disease…
Report
Hepatocellular Carcinoma – Geographic Focus: China – Hepatocellular Carcinoma – China In-Depth (China)
The hepatocellular carcinoma therapy market in China is poised to experience significant growth, driven by an aging population and the high prevalence of hepatitis B and C infection. Angiogenesis…
